Get the facts, then choose a treatment that fits your life.

When it comes to treatment for hemophilia with inhibitors, you have a therapy choice. Along with fast bleed control, you may want to consider how well your treatment fits into your lifestyle.

Here are some things to think about:

    Is it room temperature stable?


    Is it quick to mix and fast to infuse?


    How does treatment work when I’m on the go?


    Is the packaging small enough to take with me?

How does NovoSeven® RT fit your lifestyle?

Feature comparison chart between NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) and FEIBA

aFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors.
bIn patients with hemophilia A or B with inhibitors.
cIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
dPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.
All information from FEIBA Package Insert.
eRedosing time does not correlate to body weight.
fMaximum daily dose.

Travel ready, to go where you go.

Traveling is more convenient when everything you need to prepare and mix a dose comes in 1 compact box. And with multiple dose strengths, you’ll have fewer vials to transport. For storing supplies at home or to help make traveling even more convenient, get a Ready-to-Travel Case. It’s compact and ready to pack in your carry-on bag, backpack, or briefcase.

To order a Travel Kit, please contact a
Novo Nordisk representative.

To order a Travel Kit, please contact a
Novo Nordisk representative.

Ready-to-Travel Case for NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Quick to mix.

The MixPro® prefilled syringe means no extra steps to fill a syringe with diluent.

Quick to mix.

The MixPro® prefilled syringe means no extra steps to fill a syringe with diluent.

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) Box

It’s easy to get started with NovoSeven® RT.

Once you and your health care provider decide that NovoSeven® RT is right for you, we’re here to help you successfully start your treatment.

Hear from people who understand your experience.

Watch our videos to hear people with bleeding disorders talk about traveling and infusing on the go with NovoSeven® RT.

Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information.

NovoSeven® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.